Zacks Investment Research
15 Oct 2026, 16:45 UTC · 1h ago
Doximity Deepens U.S. News Alliance to Improve Patient Access to Care
Impact · against what's priced in
The extension of the U.S. News & World Report partnership is not a catalyst for DOCS. The market has already priced in a steep growth deceleration and is ignoring potential upside from new product tools; maintaining an existing legacy partnership does not provide the evidence of AI monetization or revenue re-acceleration required to shift the current valuation.
- DOCS+0.00
Already priced in
- The price assumes
Revenue growth slowing from 13.1% to roughly the 1.7% annual rate
Extending a 13-year legacy partnership to provide physician data and appointment-booking tools maintains the status quo but does not provide the growth re-acceleration the market is currently discounting.
What DOCS's price assumes · Sep 23
Search tags
